Fresenius Stock - long-term strategy in healthcare after Kabi unit sale

Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 15:45 CET. Details in the imprint.

Fresenius (DE0005785604) remains a key German healthcare group with a sharpened focus after the recent Fresenius Kabi majority sale to Novo Holdings, according to the IR release dated 12/02/2024. With no new company or analyst headlines emerging today, attention shifts to its long-term strategy and portfolio.

Portfolio reshaped after Kabi deal

The strategic shift accelerated when Fresenius agreed to sell a 50% plus one share stake in Fresenius Kabi to Novo Holdings for an enterprise value of around EUR 5.4 billion, as detailed in the transaction IR announcement.

The deal structure left Fresenius with a substantial minority interest while reducing leverage and freeing up capital. Management positioned this move as a step toward a more focused healthcare group with Fresenius Helios and Fresenius Vamed as core pillars.

Long-term business model in focus

With the Kabi transaction closing and Fresenius Medical Care deconsolidated earlier, the group now centers on hospital and post-acute care exposure through Fresenius Helios and rehabilitation activities via Vamed, according to the company’s latest annual report summary.

Analyst consensus compiled on financial portals continues to frame Fresenius as a diversified but more streamlined healthcare provider with a DAX listing and exposure to demographic trends, even if individual rating changes have been muted in recent weeks.

How the company earns its money

Fresenius generates most of its revenue from acute care and elective procedures at Helios hospitals in Germany and Spain, complemented by rehabilitation, project business and services at Vamed. Additional earnings contributions come from the remaining minority stake in Fresenius Kabi.

Where the stock trades today

The shares of Fresenius (DE0005785604) trade on Xetra at EUR 39.16 as of 06/20/2026, 13:52 CET, based on exchange data.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.